Search Ontology:
ChEBI

EC 2.7.11.30 (receptor protein serine/threonine kinase) inhibitor

Term ID
CHEBI:137123
Synonyms
  • activin receptor kinase inhibitor
  • activin receptor kinase inhibitors
  • ATP:[receptor-protein] phosphotransferase inhibitor
  • ATP:[receptor-protein] phosphotransferase inhibitors
  • EC 2.7.11.30 (receptor protein serine/threonine kinase) inhibitors
  • EC 2.7.11.30 inhibitor
  • EC 2.7.11.30 inhibitors
  • inhibitor of receptor protein serine/threonine kinase
  • receptor protein serine/threonine kinase (EC 2.7.11.30) inhibitor
  • receptor protein serine/threonine kinase (EC 2.7.11.30) inhibitors
  • receptor protein serine/threonine kinase inhibitor
  • receptor protein serine/threonine kinase inhibitors
  • receptor serine/threonine protein kinase inhibitor
  • receptor serine/threonine protein kinase inhibitors
  • receptor type I serine/threonine protein kinase inhibitor
  • receptor type I serine/threonine protein kinase inhibitors
  • receptor type II serine/threonine protein kinase inhibitor
  • receptor type II serine/threonine protein kinase inhibitors
  • STK13 inhibitor
  • STK13 inhibitors
  • TGF-beta kinase inhibitor
  • TGF-beta kinase inhibitors
(all 22)
Definition
An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the activity of receptor protein serine/threonine kinase (EC 2.7.11.30).
References
Ontology
ChEBI  ( EBI )
Relationships
is a type of
has subtype
inverse has_role
Phenotype
Phenotype resulting from EC 2.7.11.30 (receptor protein serine/threonine kinase) inhibitor
Phenotype where environments contain EC 2.7.11.30 (receptor protein serine/threonine kinase) inhibitor
Phenotype modified by environments containing EC 2.7.11.30 (receptor protein serine/threonine kinase) inhibitor
Phenotype affecting EC 2.7.11.30 (receptor protein serine/threonine kinase) inhibitor
Human Disease Model
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.